Accession Number : AD1004089

Title :   Loss of PEDF: A Novel Mechanism of Antihormone Resistance in Breast Cancer

Descriptive Note : Technical Report,01 Aug 2012,31 Jul 2015

Corporate Author : University of Kansas Medical Center Kansas City United States

Personal Author(s) : Lewis-Wambi,Joan

Full Text :

Report Date : 01 Oct 2015

Pagination or Media Count : 88

Abstract : Resistance to endocrine therapy such as tamoxifen or aromatase inhibitors is a major clinical obstacle to the effective treatment and cure of women with estrogen receptor (ER)-positive breast cancer. It is estimated that 40% of breast cancer patients will develop endocrine-resistant disease following long-term treatment. The possibility of identifying new targets for therapy in resistant disease, or patients, who may benefit from additional treatment with existing therapies, provides a strong impetus to identify markers and mediators of therapeutic resistance. Our laboratory has identified a novel protein called pigment epithelium derived factor (PEDF) that appears to be suppressed/silenced in endocrine resistant breast cancer.

Descriptors :   breast cancer , cells(biology) , MOLECULAR PROPERTIES

Distribution Statement : APPROVED FOR PUBLIC RELEASE